Physician

Irfan A Vaziri, MD, MBBS

According to 2025 Medicare claims, Irfan Vaziri, MD, MBBS (NPI: 1811900244) practices hematology/oncology in the Lincoln, NE market, with the plurality of this provider's patient population coming from Lancaster, NE. This provider's primary affiliated billing organization is CANCER PARTNERS OF NEBRASKA PC (NPI: 1437111408; TIN: 911862785) and primary practice location at 68516-5587. Vaziri is affiliated with the NPG Health Collaborative LLC (ACO ID: A3287), Bryan Health Connect ACO, LLC (ACO ID: A4573), and Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Vaziri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 514 traditional Medicare patients, billed 85,139 HCPCS/CPT codes, and received $1,273,637 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 471 prescription claims across 123 beneficiaries totaling $455,243 in drug costs, led by Xarelto (Rivaroxaban). 2023 DME data shows 13 claims. Open Payments data shows 13 records totaling $22,220. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $101,484 to $1,273,637. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,044,236 and ending at $455,243. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	561	1,879	$101,484
2016	649	2,211	$115,836
2017	596	2,046	$107,440
2018	531	1,562	$79,174
2019	86	108	$4,774
2020	385	95,950	$1,294,279
2021	596	134,422	$2,278,577
2022	709	183,350	$3,441,417
2023	580	128,280	$2,358,047
2024	514	85,139	$1,273,637

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	157	1,116	$1,044,236
2016	190	1,424	$1,667,151
2017	198	1,340	$1,836,293
2018	171	1,128	$1,587,111
2019	69	251	$237,745
2020	76	432	$956,989
2021	124	840	$2,124,815
2022	124	751	$2,747,695
2023	142	770	$2,190,313
2024	123	471	$455,243

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	28	153	$18,063
2016	N/R	46	$4,297
2017	11	11	$1,122
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	13	$245
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	188	378	$94
80053	Blood test, comprehensive group of blood chemicals	243	364	$10
36415	Insertion of needle into vein for collection of blood sample	258	410	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	310	551	$8
83615	Lactate dehydrogenase (enzyme) level	160	216	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xarelto	Rivaroxaban	19	669	$12,689
Potassium Chloride	Potassium Chloride	11	405	$850
Anastrozole	Anastrozole	35	2,233	$669
Dexamethasone	Dexamethasone	27	442	$491
Hydroxyurea	Hydroxyurea	18	652	$462

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$190	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$22,030	Karyopharm Therapeutics Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Irfan A. Vaziri, MD, MBBS?

Tedicare shows public-source Medicare data for Irfan A. Vaziri, MD, MBBS (NPI 1811900244), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Irfan A. Vaziri, MD, MBBS have ACO affiliation data?

Irfan A. Vaziri, MD, MBBS is shown with ACO affiliation data for NPG Health Collaborative LLC (MSSP, ACO ID A3287), Bryan Health Connect ACO, LLC (MSSP, ACO ID A4573), and Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Irfan A. Vaziri, MD, MBBS?

Irfan A. Vaziri, MD, MBBS is linked to CANCER PARTNERS OF NEBRASKA PC (billing NPI 1437111408) in the available physician profile data.

Does Irfan A. Vaziri, MD, MBBS have Open Payments data?

Irfan A. Vaziri, MD, MBBS has 13 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.